Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
investor.lilly.com
investor.lilly.com
4 articles from investor.lilly.com indexed by Voice Herald. Below is what investor.lilly.com covers most and which stories they have contributed to.
Latest from investor.lilly.com
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
investor.lilly.com
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
investor.lilly.com
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company
investor.lilly.com